ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Repeated Intravenous Dosing of Human Umbilical Cord Mesenchymal Stem Cells Improves Glycemic Control and Organ Protection in a Type 2 Diabetes Rat Model.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy and safety of allogeneic umbilical cord blood mononuclear cells therapy in children with autism spectrum disorder and immune dysregulation: a single-center, double-blinded, randomized, placebo-controlled trial.Stem cell research & therapy · 2026Trial
- Preclinical Toxicological evaluation of the HIV entry inhibitor peptide 2P23 as a candidate rectovaginal microbicide.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type-2 diabetes mellitus (T2DM) is a chronic disorder marked by insulin resistance, beta (β)-cell dysfunction, and persistent hyperglycemia, often leading to diabetic kidney disease. There is growing recognition that inflammation exacerbates diabetes. Human umbilical cord mesenchymal stem cells (hUC-MSCs) have shown promising immunomodulatory effects in the treatment of T2DM; however, the optimal dosing remains inconclusive. Objective: This study evaluates the effectiveness of early, late, and repeated doses of Cytopeutics Methods: Male Sprague Dawley (SD) rats were allocated into five groups: normal control group and diabetic control group receiving saline, and three diabetic treatment groups receiving hUC-MSCs at different time points-early, late, and repeated. The male rats were fed a high-fat diet (HFD), followed by diabetes induction via a single intraperitoneal injection of streptozotocin (STZ) at 35 mg/kg body weight (BW). Each treatment group received 3.5 × 10 Results: The diabetic control group exhibited significantly poorer glycemic control along with extensive pancreatic and kidney damage compared to the normal control group. The early dose group showed limited glycemic control, but reduced hs-CRP sustainably compared to the diabetic control group. The late dose group demonstrated glycemic control partially, and preserved pancreatic β-cells and kidney from damage but did not reduce hs-CRP. The repeated dose group reduced HbA1c, FSG, FUG and hs-CRP up to the end of the study and is also associated with fewer pancreatic β-cells and renal tissue damage. Conclusion: Repeated hUC-MSCs administration demonstrated better glycemic control, modulated inflammatory responses, protected β-cells and kidneys from damage in a T2DM rat model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.